UC was recently awarded two patents on CRISPR technology. UC is currently embroiled in a highly-watched dispute with the Broad Institute over who owns the heralded first patents covering CRISPR-Cas9 in plant and animal cells. (We previously blogged about the dispute here and here.) While that dispute remains pending, the question remains how important UC’s two new CRISP patents are? How much will they impact the overall intellectual-property being claimed over the burgeoning CRISPR-Cas9 technology?
Read More